Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

43. Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy)

Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) July 2017 Technology Description: Nivolumab is a drug which blocks a protein (...) , called the programmed death-1 (PD-1) receptor, on the surface of certain immune cells (called T-cells). By blocking the PD-1 receptor, nivolumab stops the cancer cells evading immune-mediated tumour destruction. This restores T-cell activity and the patient’s own immune system is able to directly fight and kill cancer cells. Nivolumab is given as a drip directly into a vein in the hand or arm. Studies of nivolumab in this population are currently being conducted to determine if its use

NIHR Innovation Observatory2017

44. Nivolumab (Opdivo) for cHL - the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

Nivolumab (Opdivo) for cHL - the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

Scottish Medicines Consortium2017

45. [Nivolumab for the treatment of advanced melanoma]

[Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nivolumab for the treatment of advanced melanoma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 543. 2017 Authors' conclusions High quality evidence showed that the use of nivolumab as first-line therapy, in patients with advanced (metastatic or irresecable) melanoma without BRAF mutations would increase the rate of one year progression

Health Technology Assessment (HTA) Database.2017

46. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 (...) tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level

NEJM2017

48. Nivolumab (Hodgkin lymphoma) - Benefit assessment according to õ35a Social Code Book V

Nivolumab (Hodgkin lymphoma) - Benefit assessment according to õ35a Social Code Book V Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76 [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V] Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76 [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76. [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a

Health Technology Assessment (HTA) Database.2017

49. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. BACKGROUND: For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic (...) viral hepatitis. METHODS: We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase

Lancet2017

52. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer 28861280 2018 11 13 2059-7029 1 4 2016 ESMO open ESMO Open Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. e000108 10.1136/esmoopen-2016-000108 Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small (...) cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC. In this multicentre phase II study, patients with advanced or recurrent non-squamous NSCLC, which had progressed after platinum-containing chemotherapy, were treated with nivolumab 3 mg/kg, intravenously every 2 weeks until progressive disease or unacceptable toxicity was observed. The primary end point was independent radiology

ESMO open2017 Full Text: Link to full Text with Trip Pro

53. Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis 29147577 2018 11 13 2059-7029 2 Suppl 1 2017 ESMO open ESMO Open Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. e000119 10.1136/esmoopen-2016-000119 Vansteenkiste Johan J Respiratory Oncology Unit, Department of Respiratory Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. eng Editorial 2017 03 07 England ESMO Open 101690685 2059-7029 2016 11 27 2017 01 11 2016

ESMO open2017 Full Text: Link to full Text with Trip Pro

54. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24]

[Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 438. 2016 Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2017

55. [Nivolumab (NSCLC) - addendum to commission A16-25]

[Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57. [Nivolumab (NSCLC) - addendum to commission A16-25] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 439. 2016 Final publication URL Indexing Status Subject indexing

Health Technology Assessment (HTA) Database.2017

56. Nivolumab in advanced melanoma treament

Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L Citation Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Nivolumab in advanced melanoma treament. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (...) (IECS). Informe de Respuesta Rapida No. 480. 2016 Authors' conclusions Moderate quality evidence showed that the use of nivolumab, when compared with dacarbazine in patients with advanced melanoma (metastatic or inoperable) would increase survival rate at one year and progression-free survival as first line. Although its use as single-agent or in combination with ipilimumab showed an increased progression-free survival, the lack of information on its impact on overall survival or comparative studies

Health Technology Assessment (HTA) Database.2017

57. Nivolumab for the treatment of non-small cell lung cancer

Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Nivolumab for the treatment of non-small cell lung cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 479. 2016 Authors' conclusions The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated

Health Technology Assessment (HTA) Database.2017